Atezolizumab A Promising Option for Early-Stage NSCLC
In patients with resected stage II-IIIA non-small cell lung cancer (NSCLC), atezolizumab showed a disease-free survival benefit versus best supporting care after adjuvant chemotherapy, with pronounced...
